Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.2, replacing Revision: v3.3.1.
    Difference
    0.1%
    Check dated 2025-11-27T23:17:57.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The Publications note now states that publications are automatically filled in from PubMed, replacing the previous wording. The revision tag was updated to Revision: v3.3.1 (replacing v3.2.0).
    Difference
    0.1%
    Check dated 2025-11-20T22:12:34.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Removed the government funding status banner from the page; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-13T15:45:01.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    No additions or deletions were detected for the Study Details page (NCT03253068). The content appears unchanged.
    Difference
    0.5%
    Check dated 2025-10-30T09:00:40.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    Page updated from Revision: v3.0.2 to Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-10-01T02:37:17.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    Version bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-30T02:53:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.